Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods

GBI Research, January 2012, Pages: 87

GBI Research, the leading business intelligence provider, has released its latest research, “Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods”, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also details immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.

GBI Research analysis shows that the global market for immunosuppressant drugs used in transplants is projected to increase at a compound annual growth rate (CAGR) of 6.7% from 2004–2010. The market is forecast to grow at a CAGR of 6.1% from 2010–2018, to reach a value of $5.6 billion in 2018. GBI Research analysis found the R&D pipeline for the immunosuppressant drug market to be moderate. The leading companies in this market, F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc., are also analyzed in this report.

Scope

- Analysis of the five major solid organ immunosuppressant drugs market which include heart transplant, pancreas transplant, lung transplant, kidney transplant and liver transplant immunosuppressant drug market
- Data and analysis of the immunosuppressant drug market in the leading regions of the world: the US, the top five countries of Europe and Japan.
- Annualized market data for the immunosuppressant drug market from 2004–2010, with forecasts to 2018.
- Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and target populations.
- Key drivers and restraints that have had a significant impact on the market.
- Pipeline analysis of the immunosuppressant drug market for the five types of transplant.
- Competitive landscape of the global immunosuppressant drug market including benchmarking of top companies. The key companies studied in this report are: F. Hoffman La Roche, Novartis AG, Genzyme Corporation and Astellas Pharma Inc.

Reasons to buy

- The report will aid business development and help marketing executives strategize product launches, and
- Build effective strategies to launch pipeline products by identifying potential geographies.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market entry and market expansion strategies by identifying geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with better efficacy and safety.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Solid Organ Transplant Immunosuppressant Market to 2018 - Introduction
2.1 Overview
2.2 GBI Research Report Guidance

3 Solid Organ Transplant Immunosuppressant Market to 2018 - Market Overview
3.1 Introduction
3.1.1 Types of Transplant
3.1.2 Transplant Rejection
3.1.3 Immunosuppressive Drug Therapy
3.2 Market Forecast
3.2.1 Market Share by Disease Sector
3.2.2 Market Share by Geography
3.3 Annual Cost of Therapy
3.4 Target Population
3.5 Solid Organ Transplant Immunosuppressant Market Drivers and Restraints
3.5.1 Drivers
3.5.2 Restraints

4 Solid Organ Transplant Immunosuppressant Market to 2018 - Geographical Landscape
4.1 The US
4.1.1 Introduction
4.1.2 Revenue
4.1.3 Annual Cost of Therapy
4.1.4 Target Population
4.2 Top Five Countries of Europe
4.2.1 Introduction
4.2.2 Revenue
4.2.3 Annual Cost of Therapy
4.2.4 Target Population
4.3 Japan
4.3.1 Introduction
4.3.2 Revenue
4.3.3 Annual Cost of Therapy
4.3.4 Target Population

5 Solid Organ Transplant Immunosuppressant Market to 2018 - Therapeutic Landscape
5.1 Heart Transplant Market
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Therapy
5.1.4 Target Population
5.2 Lung Transplant Market
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Annual Cost of Therapy
5.2.4 Target Population
5.3 Kidney Transplant Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Target Population
5.4 Liver Transplant Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Target Population
5.5 Pancreas Transplant Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Target Population

6 Solid Organ Transplant Immunosuppressant Market to 2018 - Product Pipeline Analysis
6.1 Research and Development (R&D) Pipeline by Indication
6.2 R&D Pipeline by Phase
6.3 R&D Pipeline - Heart Transplant
6.3.1 Overview
6.3.2 Pre-Clinical Phase
6.3.3 Phase II
6.3.4 Phase III
6.4 R&D Pipeline - Lung Transplant
6.4.1 Overview
6.4.2 Pre-Clinical Phase
6.4.3 Phase II
6.4.4 Phase III
6.5 R&D Pipeline - Kidney Transplant
6.5.1 Overview
6.5.2 Pre-Clinical Phase
6.5.3 Phase I
6.5.4 Phase II
6.5.5 Phase III
6.6 R&D Pipeline - Liver Transplant
6.6.1 Overview
6.6.2 Pre-Clinical Phase
6.6.3 Phase II
6.6.4 Phase I
6.6.5 Pre-Clinical Phase
6.7 R&D Pipeline - Pancreas Transplant
6.7.1 Overview
6.7.2 Phase II
6.7.3 Phase III

7 Solid Organ Transplant Immunosuppressant Market to 2018 - Marketed Products
7.1 Prograf
7.1.1 Overview
7.1.2 Safety
7.1.3 Efficacy
7.2 Cellcept
7.2.1 Overview
7.2.2 Safety
7.2.3 Efficacy
7.3 Myfortic
7.3.1 Overview
7.3.2 Safety
7.3.3 Efficacy
7.4 Neoral
7.4.1 Overview
7.4.2 Safety
7.4.3 Efficacy
7.5 Zenapax
7.5.1 Overview
7.5.2 Safety
7.5.3 Efficacy

8 Solid Organ Transplant Immunosuppressant Market to 2018 - Competitive Landscape
8.1 F. Hoffman La Roche
8.1.1 Overview
8.1.2 Marketed Products
8.1.3 SWOT Analysis
8.2 Novartis AG
8.2.1 Overview
8.2.2 Marketed Products
8.2.3 SWOT Analysis
8.3 Genzyme Corporation
8.3.1 Overview
8.3.2 Marketed Products
8.3.3 SWOT Analysis
8.4 Astellas Pharma Inc.
8.4.1 Overview
8.4.2 Marketed Products
8.4.3 SWOT Analysis

9 Solid Organ Transplant Immunosuppressant Market to 2018 - Strategic Consolidations
9.1 Segmentation by Type
9.2 Segmentation by Year
9.3 Segmentation by Indication
9.4 Segmentation by Geography
9.5 Segmentation by Deal Value
9.6 Major M&As
9.7 Major Licensing Agreements
9.8 Major Co-Development Deals

10 Solid Organ Transplant Immunosuppressant Market to 2018 -Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Therapeutic Landscape
10.3.5 Market Size by Geography
10.3.6 Geographical Landscape
10.3.7 Pipeline Analysis
10.3.8 Competitive Landscape
10.3.9 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources

1.1 List of Tables
Table 1: Solid Organ Transplant Immunosuppressant Market, Global, Revenue ($bn), 2004-2010
Table 2: Solid Organ Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2010-2018
Table 3: Solid Organ Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010
Table 4: Solid Organ Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018
Table 5: Solid Organ Transplant Immunosuppressant Market, Global, Target Population, 2004-2010
Table 6: Solid Organ Transplant Immunosuppressant Market, Global, Target Population, 2010-2018
Table 7: Solid Organ Transplant Immunosuppressant Market, The US, Revenue ($bn), 2004-2010
Table 8: Solid Organ Transplant Immunosuppressant Market, The US, Revenue Forecast ($bn), 2010-2018
Table 9: Solid Organ Transplant Immunosuppressant Market, The US, Annual Cost of Therapy ($), 2004-2010
Table 10: Solid Organ Transplant Immunosuppressant Market, The US, Annual Cost of Therapy ($), 2010-2018
Table 11: Solid Organ Transplant Immunosuppressant Market, The US, Target Population, 2004-2010
Table 12: Solid Organ Transplant Immunosuppressant Market, The US, Target Population, 2010-2018
Table 13: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Revenue ($m), 2004-2010
Table 14: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2018
Table 15: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004-2010
Table 16: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2018
Table 17: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Target Population, 2004-2010
Table 18: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Target Population, 2010-2018
Table 19: Solid Organ Transplant Immunosuppressant Market, Japan, Revenue ($m), 2004-2010
Table 20: Solid Organ Transplant Immunosuppressant Market, Japan, Revenue Forecast ($m), 2010-2018
Table 21: Solid Organ Transplant Immunosuppressant Market, Japan, Annual Cost of Therapy ($), 2004-2010
Table 22: Solid Organ Transplant Immunosuppressant Market, Japan, Annual Cost of Therapy ($), 2010-2018
Table 23: Solid Organ Transplant Immunosuppressant Market, Japan, Target Population, 2004-2010
Table 24: Solid Organ Transplant Immunosuppressant Market, Japan, Target Population, 2010-2018
Table 25: Heart Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010
Table 26: Heart Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018
Table 27: Heart Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010
Table 28: Heart Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018
Table 29: Heart Transplant Immunosuppressant Market, Global, Target Population, 2004-2010
Table 30: Heart Transplant Immunosuppressant Market, Global, Target Population, 2010-2018
Table 31: Lung Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010
Table 32: Lung Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018
Table 33: Lung Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010
Table 34: Lung Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018
Table 35: Lung Transplant Immunosuppressant Market, Global, Target Population, 2004-2010
Table 36: Lung Transplant Immunosuppressant Market, Global, Target Population, 2010-2018
Table 37: Kidney Transplant Immunosuppressant Market, Global, Revenue ($bn), 2004-2010
Table 38: Kidney Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2010-2018
Table 39: Kidney Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010
Table 40: Kidney Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018
Table 41: Kidney Transplant Immunosuppressant Market, Global, Target Population, 2004-2010
Table 42: Kidney Transplant Immunosuppressant Market, Global, Target Population, 2010-2018
Table 43: Liver Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010
Table 44: Liver Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018
Table 45: Liver Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2010
Table 46: Liver Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2010-2018
Table 47: Liver Transplant Immunosuppressant Market, Global, Target Population, 2004-2010
Table 48: Liver Transplant Immunosuppressant Market, Global, Target Population, 2010-2018
Table 49: Pancreas Transplant Immunosuppressant Market, Global, Revenue ($m), 2004-2010
Table 50: Pancreas Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2010-2018
Table 51: Pancreas Transplant Immunosuppressant Market, Global, ANNUAL COST OF THERAPY ($), 2004-2010
Table 52: Pancreas Transplant Immunosuppressant Market, Global, ANNUAL COST OF THERAPY ($), 2010-2018
Table 53: Pancreas Transplant Immunosuppressant Market, Global, Target Population, 2004-2010
Table 54: Pancreas Transplant Immunosuppressant Market, Global, Target Population, 2010-2018
Table 55: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Indication (%), 2011
Table 56: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Table 57: Heart Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Table 58: Heart Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011
Table 59: Heart Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011
Table 60: Heart Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011
Table 61: Lung Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Table 62: Lung Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011
Table 63: Lung Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011
Table 64: Lung Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011
Table 65: Kidney Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Table 66: Kidney Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011
Table 67: Kidney Transplant Immunosuppressant Market, Global, Phase I Pipeline Molecules, 2011
Table 68: Kidney Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011
Table 69: Kidney Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011
Table 70: Liver Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Table 71: Liver Transplant Immunosuppressant Market, Global, Pre-Clinical Pipeline Molecules, 2011
Table 72: Liver Transplant Immunosuppressant Market, Global, Phase I Pipeline Molecules, 2011
Table 73: Liver Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011
Table 74: Liver Transplant Immunosuppressant Market, Global, Phase III Pipeline Molecules, 2011
Table 75: Pancreas Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Table 76: Pancreas Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011
Table 77: Pancreas Transplant Immunosuppressant Market, Global, Phase II Pipeline Molecules, 2011
Table 78: Solid Organ Transplant Immunosuppressant Market, Marketed Products, F. Hoffman La Roche, 2011
Table 79: Solid Organ Transplant Immunosuppressant Market, Marketed Products, Novartis AG, 2011
Table 80: Solid Organ Transplant Immunosuppressant Market, Marketed Products, F. Genzyme Corporation, 2011
Table 81: Solid Organ Transplant Immunosuppressant Market, Marketed Products, Astellas Pharma Inc., 2011
Table 82: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Type (%), 2004-2011
Table 83: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Year, 2004-2011
Table 84: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Indication, 2004-2011
Table 85: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Geography, 2004-2011
Table 86: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Value (million), 2004-2011
Table 87: Solid Organ Transplant Immunosuppressant Market, Global, Major M&A Deals, 2011
Table 88: Solid Organ Transplant Immunosuppressant Market, Global, Major Licensing Deals, 2009-2011
Table 89: Solid Organ Transplant Immunosuppressant Market, Global, Major Co-Development Deals, 2009-2011

1.2 List of Figures
Figure 1: Solid Organ Transplant Immunosuppressant Market, Types of Transplant, 2011
Figure 2: Solid Organ Transplant Immunosuppressant Market, Classification of Immunosuppressant Drugs, 2011
Figure 3: Solid Organ Transplant Immunosuppressant Market, Immunosuppressant Drug Monitoring, 2011
Figure 4: Solid Organ Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2004-2018
Figure 5: Solid Organ Transplant Immunosuppressant Market, Global, Market Share by Disease Segment, 2010
Figure 6: Solid Organ Transplant Immunosuppressant Market, Global, Market Share by Geography, 2010
Figure 7: Solid Organ Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018
Figure 8: Solid Organ Transplant Immunosuppressant Market, Global, Target Population, 2004-2018
Figure 9: Solid Organ Transplant Immunosuppressant Market, Drivers and Restraints, 2011
Figure 10: Solid Organ Transplant Immunosuppressant Market, The US, Revenue Forecast ($bn), 2004-2018
Figure 11: Solid Organ Transplant Immunosuppressant Market, The US, Annual Cost of Therapy ($), 2004-2018
Figure 12: Solid Organ Transplant Immunosuppressant Market, The US, Target Population, 2004-2018
Figure 13: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Revenue Forecast ($m), 2004-2018
Figure 14: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2004-2018
Figure 15: Solid Organ Transplant Immunosuppressant Market, Top Five Countries of Europe, Target Population, 2004-2018
Figure 16: Solid Organ Transplant Immunosuppressant Market, Japan, Revenue Forecast ($m), 2004-2018
Figure 17: Solid Organ Transplant Immunosuppressant Market, Japan, Annual Cost of Therapy ($), 2004-2018
Figure 18: Solid Organ Transplant Immunosuppressant Market, Japan, Target Population, 2004-2018
Figure 19: Heart Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018
Figure 20: Heart Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018
Figure 21: Heart Transplant Immunosuppressant Market, Global, Target Population, 2004-2018
Figure 22: Lung Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018
Figure 23: Lung Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018
Figure 24: Lung Transplant Immunosuppressant Market, Global, Target Population, 2004-2018
Figure 25: Kidney Transplant Immunosuppressant Market, Global, Revenue Forecast ($bn), 2004-2018
Figure 26: Kidney Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018
Figure 27: Kidney Transplant Immunosuppressant Market, Global, Target Population, 2004-2018
Figure 28: Liver Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018
Figure 29: Liver Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018
Figure 30: Liver Transplant Immunosuppressant Market, Global, Target Population, 2004-2018
Figure 31: Pancreas Transplant Immunosuppressant Market, Global, Revenue Forecast ($m), 2004-2018
Figure 32: Pancreas Transplant Immunosuppressant Market, Global, Annual Cost of Therapy ($), 2004-2018
Figure 33: Pancreas Transplant Immunosuppressant Market, Global, Target Population, 2004-2018
Figure 34: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Indication (%), 2011
Figure 35: Solid Organ Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Figure 36: Heart Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Figure 37: Lung Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Figure 38: Kidney Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Figure 39: Liver Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Figure 40: Pancreas Transplant Immunosuppressant Market, Global, Pipeline Molecules by Phase (%), 2011
Figure 41: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, F. Hoffman La Roche, 2011
Figure 42: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, Novartis AG, 2011
Figure 43: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, Genzyme Corporation, 2011
Figure 44: Solid Organ Transplant Immunosuppressant Market, SWOT Analysis, Astellas Pharma Inc., 2011
Figure 45: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Type (%), 2004-2011
Figure 46: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Year, 2004-2011
Figure 47: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Indication, 2004-2011
Figure 48: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Geography, 2004-2011
Figure 49: Solid Organ Transplant Immunosuppressant Market, Global, Deals by Value (million), 2004-2011
Figure 50: GBI Research Market Forecasting Model

GBI Research, the leading business intelligence provider, has released its latest research, “Solid Organ Transplant Immunosuppressant Market to 2018 - Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods”, which provides insight into the global solid organ transplant immunosuppressant drug market until 2018. The report provides an in-depth analysis of the following five transplant areas: heart, lung, pancreas, liver and kidney. It also provides information in the immunosuppressant drug markets in the following key regions: the US, the top five countries of Europe and Japan. The report also includes details about immunosuppressant drug R&D pipelines.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The Global Immunosuppressant Drugs Market will Grow Steadily with Few Promising Products in the Pipeline

The immunosuppressant drugs market is a steadily growing market and the growth rate is expected to remain the steady in the forecast period too. Lack of innovative pipeline implies that market is unlikely to witness sharp growth. Existing leading immunosuppressant drugs are undergoing lifecycle management projects for new indications.

Limited Supplies of Organs Drives Procurement and Preservation Techniques

Medical procedures for organ transplants have evolved due to recent advances in organ preservation and procurement techniques. Survival rates have increased steadily for most patients and for both organs and grafts, as these factors alter the probability of a return to normal organ function. Furthermore, innovations in organ preservation techniques allow greater flexibility, which provides more time for complex and interdisciplinary transplant procedures and processes. In addition to this, transportation of an organ between medical centers is now possible, patients can be called in even if they are not hospitalized and there is adequate preparation time for the patient and the surgical team.

Market Share of Immunosuppressant Drugs in Japan is Low Due to Ethical, Religious and Philosophical Barriers

Japan is the smallest market for solid organ transplant immunosuppressive drugs, contributing just 0.8% to the global market share in 2010. This is due to a number of factors, such as the unique views and ideologies of Japanese people regarding death, life, ethics and religion. Another major reason was a failed attempt by Dr. Wada, Japan’s first heart transplant surgeon, while performing heart transplant from a brain-dead patient in 1968. This raised concerns about the evaluation of what constitutes brain-death resulting in a subsequent 30 year ban on cadaveric organ donation in Japan, which halted further developments in organ transplantation.

- F. Hoffman La Roche
- Novartis AG
- Genzyme Corporation
- Astellas Pharma Inc.

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Cell Therapy - Technologies, Markets and Companies
• Cellular Therapy and Cord Blood 2013 Market Report
• Proteomics - Global Strategic Business Report
• Probiotics - Global Strategic Business Report
• Tissue Engineering: The Combination of Cells & Engineering - A Global Market Overview
• Stem Cell Research - Global Business Strategic Report
• Gene Amplification Technologies - Global Strategic Business Report
• Immunoassay Systems - Global Business Strategic Report
• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• Apoptosis - Global Strategic Business Report